<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37446372</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>13</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>07</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Implication of Central Nervous System Barrier Impairment in Amyotrophic Lateral Sclerosis: Gender-Related Difference in Patients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">11196</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms241311196</ELocationID><Abstract><AbstractText>Central nervous system (CNS) barrier impairment has been reported in amyotrophic lateral sclerosis (ALS), highlighting its potential significance in the disease. In this context, we aim to shed light on its involvement in the disease, by determining albumin quotient (QAlb) at the time of diagnosis of ALS in a large cohort of patients. Patients from the university hospital of Tours (<i>n</i> = 307) were included in this monocentric, retrospective study. In total, 92 patients (30%) had elevated QAlb levels. This percentage was higher in males (43%) than in females (15%). Interestingly, QAlb was not associated with age of onset, age at sampling or diagnostic delay. However, we found an association with ALS functional rating scale-revised (ALSFRS-r) at diagnosis but this was significant only in males. The QAlb levels were not linked to the presence of a pathogenic mutation. Finally, we performed a multivariate survival analysis and found that QAlb was significantly associated with survival in male patients (HR = 2.3, 95% CI = 1.2-4.3, <i>p</i> = 0.009). A longitudinal evaluation of markers of barrier impairment, in combination with inflammatory biomarkers, could give insight into the involvement of CNS barrier impairment in the pathogenesis of the disease. The gender difference might guide the development of new drugs and help personalise the treatment of ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alarcan</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMR 1253 iBrain, Universit&#xe9; de Tours, Inserm, 10 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vourc'h</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMR 1253 iBrain, Universit&#xe9; de Tours, Inserm, 10 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berton</LastName><ForeName>Lise</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benz-De Bretagne</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piver</LastName><ForeName>Eric</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7101-0121</Identifier><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andres</LastName><ForeName>Christian R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMR 1253 iBrain, Universit&#xe9; de Tours, Inserm, 10 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UMR 1253 iBrain, Universit&#xe9; de Tours, Inserm, 10 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de Neurologie, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veyrat-Durebex</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4512-2303</Identifier><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMR 1253 iBrain, Universit&#xe9; de Tours, Inserm, 10 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasco</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMR 1253 iBrain, Universit&#xe9; de Tours, Inserm, 10 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057210" MajorTopicYN="N">Delayed Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">QAlb</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">blood&#x2013;brain barrier</Keyword><Keyword MajorTopicYN="N">central nervous system barrier</Keyword><Keyword MajorTopicYN="N">spinal cord barrier</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>14</Day><Hour>13</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>14</Day><Hour>1</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37446372</ArticleId><ArticleId IdType="pmc">PMC10342931</ArticleId><ArticleId IdType="doi">10.3390/ijms241311196</ArticleId><ArticleId IdType="pii">ijms241311196</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Feldman E.L., Goutman S.A., Petri S., Mazzini L., Savelieff M.G., Shaw P.J., Sobue G. Amyotrophic lateral sclerosis. Lancet. 2022;400:1363&#x2013;1380. doi: 10.1016/S0140-6736(22)01272-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01272-7</ArticleId><ArticleId IdType="pmc">PMC10089700</ArticleId><ArticleId IdType="pubmed">36116464</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman S.A., Hardiman O., Al-Chalabi A., Chi&#xf3; A., Savelieff M.G., Kiernan M.C., Feldman E.L. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol. 2022;21:465&#x2013;479. doi: 10.1016/S1474-4422(21)00414-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00414-2</ArticleId><ArticleId IdType="pmc">PMC9513754</ArticleId><ArticleId IdType="pubmed">35334234</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., van den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Prim. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasquali L., Lenzi P., Biagioni F., Siciliano G., Fornai F. Cell to cell spreading of misfolded proteins as a therapeutic target in motor neuron disease. Curr. Med. Chem. 2014;21:3508&#x2013;3534. doi: 10.2174/0929867321666140601161534.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867321666140601161534</ArticleId><ArticleId IdType="pubmed">24934358</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw P.J., Ince P.G. Glutamate, excitotoxicity and amyotrophic lateral sclerosis. J. Neurol. 1997;244((Suppl. 2)):S3&#x2013;S14. doi: 10.1007/BF03160574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03160574</ArticleId><ArticleId IdType="pubmed">9178165</ArticleId></ArticleIdList></Reference><Reference><Citation>Robberecht W. Oxidative stress in amyotrophic lateral sclerosis. J. Neurol. 2000;247((Suppl. 1)):I1&#x2013;I6. doi: 10.1007/s004150050551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004150050551</ArticleId><ArticleId IdType="pubmed">10795881</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Appel S.H. Immune dysregulation in amyotrophic lateral sclerosis: Mechanisms and emerging therapies. Lancet Neurol. 2019;18:211&#x2013;220. doi: 10.1016/S1474-4422(18)30394-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarcan H., Al Ojaimi Y., Lanznaster D., Escoffre J.-M., Corcia P., Vourc&#x2019;h P., Andres C.R., Veyrat-Durebex C., Blasco H. Taking Advantages of Blood&#x2013;Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS? J. Pers. Med. 2022;12:1071. doi: 10.3390/jpm12071071.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12071071</ArticleId><ArticleId IdType="pmc">PMC9319288</ArticleId><ArticleId IdType="pubmed">35887567</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott N.J., Patabendige A.A.K., Dolman D.E.M., Yusof S.R., Begley D.J. Structure and function of the blood-brain barrier. Neurobiol. Dis. 2010;37:13&#x2013;25. doi: 10.1016/j.nbd.2009.07.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2009.07.030</ArticleId><ArticleId IdType="pubmed">19664713</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S., Hernandez-Ontiveros D.G., Rodrigues M.C.O., Haller E., Frisina-Deyo A., Mirtyl S., Sallot S., Saporta S., Borlongan C.V., Sanberg P.R. Impaired blood-brain/spinal cord barrier in ALS patients. Brain Res. 2012;1469:114&#x2013;128. doi: 10.1016/j.brainres.2012.05.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.05.056</ArticleId><ArticleId IdType="pubmed">22750125</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S., Haller E., Saporta S., Kolomey I., Nicosia S.V., Sanberg P.R. Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res. 2007;1157:126&#x2013;137. doi: 10.1016/j.brainres.2007.04.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.04.044</ArticleId><ArticleId IdType="pubmed">17512910</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S., Saporta S., Haller E., Kolomey I., Bennett S.P., Potter H., Sanberg P.R. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS ONE. 2007;2:e1205. doi: 10.1371/journal.pone.0001205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0001205</ArticleId><ArticleId IdType="pmc">PMC2075163</ArticleId><ArticleId IdType="pubmed">18030339</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Y., Nicolazzo J.A. Altered blood&#x2013;brain barrier and blood&#x2013;spinal cord barrier dynamics in amyotrophic lateral sclerosis: Impact on medication efficacy and safety. Br. J. Pharmacol. 2022;179:2577&#x2013;2588. doi: 10.1111/bph.15802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15802</ArticleId><ArticleId IdType="pubmed">35048358</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirian A., Moszczynski A., Soleimani S., Aubert I., Zinman L., Abrahao A. Breached Barriers: A Scoping Review of Blood-Central Nervous System Barrier Pathology in Amyotrophic Lateral Sclerosis. Front. Cell. Neurosci. 2022;16:851563. doi: 10.3389/fncel.2022.851563.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2022.851563</ArticleId><ArticleId IdType="pmc">PMC9009245</ArticleId><ArticleId IdType="pubmed">35431812</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadry H., Noorani B., Cucullo L. A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS. 2020;17:69. doi: 10.1186/s12987-020-00230-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12987-020-00230-3</ArticleId><ArticleId IdType="pmc">PMC7672931</ArticleId><ArticleId IdType="pubmed">33208141</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Petzold A., S&#xfc;ssmuth S.D., Ludolph A.C., Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology. 2006;66:852&#x2013;856. doi: 10.1212/01.wnl.0000203120.85850.54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000203120.85850.54</ArticleId><ArticleId IdType="pubmed">16567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Prell T., Vlad B., Gaur N., Stubendorff B., Grosskreutz J. Blood-Brain Barrier Disruption Is Not Associated With Disease Aggressiveness in Amyotrophic Lateral Sclerosis. Front. Neurosci. 2021;15:656456. doi: 10.3389/fnins.2021.656456.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.656456</ArticleId><ArticleId IdType="pmc">PMC8586537</ArticleId><ArticleId IdType="pubmed">34776835</ArticleId></ArticleIdList></Reference><Reference><Citation>Meucci G., Rossi G., Bettini R., Montanaro D., Gironelli L., Voci L., Bianchi F. Laser nephelometric evaluation of albumin, IgG and alpha 2-macroglobulin: Applications to the study of alterations of the blood-brain barrier. J. Neurol. Sci. 1993;118:73&#x2013;78. doi: 10.1016/0022-510X(93)90248-W.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(93)90248-W</ArticleId><ArticleId IdType="pubmed">7693877</ArticleId></ArticleIdList></Reference><Reference><Citation>Assialioui A., Dom&#xed;nguez R., Ferrer I., Andr&#xe9;s-Benito P., Povedano M. Elevated Cerebrospinal Fluid Proteins and Albumin Determine a Poor Prognosis for Spinal Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2022;23:11063. doi: 10.3390/ijms231911063.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231911063</ArticleId><ArticleId IdType="pmc">PMC9570498</ArticleId><ArticleId IdType="pubmed">36232365</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J.-Y., Cai Z.-Y., Sun X.-H., Shen D.-C., Yang X.-Z., Liu M.-S., Cui L.-Y. Blood-brain barrier dysfunction and myelin basic protein in survival of amyotrophic lateral sclerosis with or without frontotemporal dementia. Neurol. Sci. 2022;43:3201&#x2013;3210. doi: 10.1007/s10072-021-05731-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-021-05731-z</ArticleId><ArticleId IdType="pubmed">34826032</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F., Ferrari I., Maranzano A., Ciusani E., Torre S., Milone I., Colombo E., Doretti A., Peverelli S., Ratti A., et al. Relationship between cerebrospinal fluid/serum albumin quotient and phenotype in amyotrophic lateral sclerosis: A retrospective study on 328 patients. Neurol. Sci. 2023;44:1679&#x2013;1685. doi: 10.1007/s10072-023-06604-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-023-06604-3</ArticleId><ArticleId IdType="pubmed">36646859</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z., Deane R., Ali Z., Parisi M., Shapovalov Y., O&#x2019;Banion M.K., Stojanovic K., Sagare A., Boillee S., Cleveland D.W., et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat. Neurosci. 2008;11:420&#x2013;422. doi: 10.1038/nn2073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2073</ArticleId><ArticleId IdType="pmc">PMC2895310</ArticleId><ArticleId IdType="pubmed">18344992</ArticleId></ArticleIdList></Reference><Reference><Citation>Pun P.B.L., Lu J., Moochhala S. Involvement of ROS in BBB dysfunction. Free Radic. Res. 2009;43:348&#x2013;364. doi: 10.1080/10715760902751902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10715760902751902</ArticleId><ArticleId IdType="pubmed">19241241</ArticleId></ArticleIdList></Reference><Reference><Citation>Obermeier B., Daneman R., Ransohoff R.M. Development, maintenance and disruption of the blood-brain barrier. Nat. Med. 2013;19:1584&#x2013;1596. doi: 10.1038/nm.3407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3407</ArticleId><ArticleId IdType="pmc">PMC4080800</ArticleId><ArticleId IdType="pubmed">24309662</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X., Hussain B., Chang J. Peripheral inflammation and blood-brain barrier disruption: Effects and mechanisms. CNS Neurosci. Ther. 2021;27:36&#x2013;47. doi: 10.1111/cns.13569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.13569</ArticleId><ArticleId IdType="pmc">PMC7804893</ArticleId><ArticleId IdType="pubmed">33381913</ArticleId></ArticleIdList></Reference><Reference><Citation>Labus J., W&#xf6;ltje K., Stolte K.N., H&#xe4;ckel S., Kim K.S., Hildmann A., Danker K. IL-1&#x3b2; promotes transendothelial migration of PBMCs by upregulation of the FN/&#x3b1;5&#x3b2;1 signalling pathway in immortalised human brain microvascular endothelial cells. Exp. Cell Res. 2018;373:99&#x2013;111. doi: 10.1016/j.yexcr.2018.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2018.10.002</ArticleId><ArticleId IdType="pubmed">30342992</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamudio F., Loon A.R., Smeltzer S., Benyamine K., Navalpur Shanmugam N.K., Stewart N.J.F., Lee D.C., Nash K., Selenica M.-L.B. TDP-43 mediated blood-brain barrier permeability and leukocyte infiltration promote neurodegeneration in a low-grade systemic inflammation mouse model. J. Neuroinflamm. 2020;17:283. doi: 10.1186/s12974-020-01952-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-020-01952-9</ArticleId><ArticleId IdType="pmc">PMC7519496</ArticleId><ArticleId IdType="pubmed">32979923</ArticleId></ArticleIdList></Reference><Reference><Citation>Staats K.A., Borchelt D.R., Tansey M.G., Wymer J. Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis. Mol. Neurodegener. 2022;17:11. doi: 10.1186/s13024-022-00515-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-022-00515-1</ArticleId><ArticleId IdType="pmc">PMC8785449</ArticleId><ArticleId IdType="pubmed">35073950</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney M.D., Zhao Z., Montagne A., Nelson A.R., Zlokovic B.V. Blood-Brain Barrier: From Physiology to Disease and Back. Physiol. Rev. 2019;99:21&#x2013;78. doi: 10.1152/physrev.00050.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00050.2017</ArticleId><ArticleId IdType="pmc">PMC6335099</ArticleId><ArticleId IdType="pubmed">30280653</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney M.D., Sagare A.P., Zlokovic B.V. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol. 2018;14:133&#x2013;150. doi: 10.1038/nrneurol.2017.188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2017.188</ArticleId><ArticleId IdType="pmc">PMC5829048</ArticleId><ArticleId IdType="pubmed">29377008</ArticleId></ArticleIdList></Reference><Reference><Citation>Parrado-Fern&#xe1;ndez C., Blennow K., Hansson M., Leoni V., Cedazo-Minguez A., Bj&#xf6;rkhem I. Evidence for sex difference in the CSF/plasma albumin ratio in ~20 000 patients and 335 healthy volunteers. J. Cell. Mol. Med. 2018;22:5151&#x2013;5154. doi: 10.1111/jcmm.13767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.13767</ArticleId><ArticleId IdType="pmc">PMC6156389</ArticleId><ArticleId IdType="pubmed">30054982</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellazzi M., Morotti A., Tamborino C., Alessi F., Pilotto S., Baldi E., Caniatti L.M., Trentini A., Casetta I., Granieri E., et al. Increased age and male sex are independently associated with higher frequency of blood&#x2013;cerebrospinal fluid barrier dysfunction using the albumin quotient. Fluids Barriers CNS. 2020;17:14. doi: 10.1186/s12987-020-0173-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12987-020-0173-2</ArticleId><ArticleId IdType="pmc">PMC7003357</ArticleId><ArticleId IdType="pubmed">32024544</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin H., Wan Q., Tian Y., Zhao B., Deng Y. Female Hormone 17&#x3b2;-Estradiol Downregulated MMP-2 Expression and Upregulated A1PI Expression in Human Corneal Stromal Cells. Cell Biochem. Biophys. 2018;76:265&#x2013;271. doi: 10.1007/s12013-017-0790-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12013-017-0790-9</ArticleId><ArticleId IdType="pubmed">28332021</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe P.A., Henderson R.D. Effects of gender in amyotrophic lateral sclerosis. Gend. Med. 2010;7:557&#x2013;570. doi: 10.1016/j.genm.2010.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genm.2010.11.010</ArticleId><ArticleId IdType="pubmed">21195356</ArticleId></ArticleIdList></Reference><Reference><Citation>Maggioli E., McArthur S., Mauro C., Kieswich J., Kusters D.H.M., Reutelingsperger C.P.M., Yaqoob M., Solito E. Estrogen protects the blood&#x2013;brain barrier from inflammation-induced disruption and increased lymphocyte trafficking. Brain Behav. Immun. 2016;51:212&#x2013;222. doi: 10.1016/j.bbi.2015.08.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2015.08.020</ArticleId><ArticleId IdType="pubmed">26321046</ArticleId></ArticleIdList></Reference><Reference><Citation>Ide T., Tsutsui H., Ohashi N., Hayashidani S., Suematsu N., Tsuchihashi M., Tamai H., Takeshita A. Greater Oxidative Stress in Healthy Young Men Compared With Premenopausal Women. Arterioscler. Thromb. Vasc. Biol. 2002;22:438&#x2013;442. doi: 10.1161/hq0302.104515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/hq0302.104515</ArticleId><ArticleId IdType="pubmed">11884287</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed L.A., Markandaiah S.S., Bonanno S., Pasinelli P., Trotti D. Excess glutamate secreted from astrocytes drives upregulation of P-glycoprotein in endothelial cells in amyotrophic lateral sclerosis. Exp. Neurol. 2019;316:27&#x2013;38. doi: 10.1016/j.expneurol.2019.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2019.04.002</ArticleId><ArticleId IdType="pmc">PMC6506236</ArticleId><ArticleId IdType="pubmed">30974102</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Y., Kagawa Y., Sun J., Turner B.J., Huang C., Shah A.D., Schittenhelm R.B., Nicolazzo J.A. Altered Blood-Brain Barrier Dynamics in the C9orf72 Hexanucleotide Repeat Expansion Mouse Model of Amyotrophic Lateral Sclerosis. Pharmaceutics. 2022;14:2803. doi: 10.3390/pharmaceutics14122803.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14122803</ArticleId><ArticleId IdType="pmc">PMC9783795</ArticleId><ArticleId IdType="pubmed">36559296</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;nig T., Wurm R., Parvizi T., Silvaieh S., Hotzy C., Cetin H., Klotz S., Gelpi E., Bancher C., Benke T., et al. C9orf72 repeat length might influence clinical sub-phenotypes in dementia patients. Neurobiol. Dis. 2022;175:105927. doi: 10.1016/j.nbd.2022.105927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2022.105927</ArticleId><ArticleId IdType="pubmed">36379394</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L. World Federation of Neurology Research Group on Motor Neuron Diseases El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral. Scler. Other Motor. Neuron. Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Claus A., Kassubek J., Tumani H. Isolated blood-cerebrospinal fluid barrier dysfunction: Prevalence and associated diseases. J. Neurol. 2005;252:1067&#x2013;1073. doi: 10.1007/s00415-005-0817-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-005-0817-9</ArticleId><ArticleId IdType="pubmed">15789126</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>